DAVID C DOSIK
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology BROOKLYN, NY NPI 1770534653
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NY PFIZER INC. All categories
General Payments — all program years on this page
$8,987.18
- Category: General Payments
- Program years: PY2018–2024
- Record count: 432
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,136.05 across 50 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,036.06 | 49 |
| Education | $99.99 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $126.52 | 2 |
| Celgene Corporation | $97.01 | 4 |
| GlaxoSmithKline, LLC. | $80.39 | 3 |
| ABBVIE INC. | $77.75 | 4 |
| Ipsen Biopharmaceuticals, Inc | $67.53 | 2 |
| Daiichi Sankyo Inc. | $60.25 | 3 |
| EISAI INC. | $50.37 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $47.53 | 3 |
| Incyte Corporation | $44.39 | 2 |
| TAIHO ONCOLOGY, INC. | $42.72 | 2 |
| Astellas Pharma US Inc | $41.85 | 3 |
| ARRAY BIOPHARMA INC | $39.91 | 2 |
| Acerta Pharma LLC | $29.51 | 1 |
| Merck Sharp & Dohme Corporation | $26.56 | 1 |
| E.R. Squibb & Sons, L.L.C. | $23.11 | 1 |
| SOBI, INC | $22.14 | 1 |
| SpringWorks Therapeutics, Inc. | $21.87 | 1 |
| Coherus Biosciences Inc. | $21.65 | 1 |
| Regeneron Healthcare Solutions, Inc. | $21.25 | 1 |
| Kite Pharma, Inc. | $19.76 | 1 |
| Stemline Therapeutics Inc. | $19.23 | 1 |
| Janssen Biotech, Inc. | $18.95 | 1 |
| Telix Pharmaceuticals | $18.81 | 1 |
| Verity Pharmaceuticals Inc. | $18.63 | 1 |
| Dendreon Pharmaceuticals LLC | $17.98 | 1 |
| JAZZ PHARMACEUTICALS INC. | $17.28 | 1 |
| GENZYME CORPORATION | $16.72 | 1 |
| Octapharma USA, Inc. | $16.60 | 1 |
| Emmaus Medical, Inc. | $16.07 | 1 |
| Gilead Sciences, Inc. | $13.71 | 1 |
By program year
Records — PY2024 (50)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.